Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.642
Peer-review started: March 26, 2016
First decision: June 6, 2016
Revised: June 21, 2016
Accepted: July 20, 2016
Article in press: July 22, 2016
Published online: September 15, 2016
Core tip: The development of molecular targeted agents contributes to prolonging survival of patients with metastatic colorectal cancer (mCRC). One anti-vascular endothelial growth factor agent, bevacizumab, and two anti-epidermal growth factor receptor (EGFR) agents, cetuximab and panitumumab, have demonstrated clinical benefits in first-line, second-line, or salvage therapy in combination with cytotoxic chemotherapy. Moreover, RAS mutation has been proven to be a negative biomarker for anti-EGFR therapy in recent retrospective analyses. This article summarizes the evidence from large clinical trials and highlights the benefit of the molecular targeted agents in patients with mCRC.